Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability of Apixaban Crushed Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Healthy participants as determined by no clinically significant deviation from normal in findings of medical history, physical examination, electrocardiograms, vital signs, and clinical laboratory tests.~* Women of childbearing potential allowed. Must be following highly effective methods of contraception~Exclusion Criteria:~* Any significant acute or chronic medical illness~* History of significant head injury within the last 2 years, including individuals with base of skull fractures~* Any major surgery within 4 weeks of study drug administration or anticipated within 2 weeks after completion of the study~* Any gastrointestinal (GI) surgery or GI disease that could impact absorption of study drug~* History of Gilbert's Syndrome~* Inability to tolerate oral medication~* Inability to be venipunctured and/or tolerate venous access~* Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study drug administration~* Any laboratory test results outside of the range of normal, confirmed by repeat results of:~  * Platelet count \<150,000 cells/µL~ * Activated partial thromboplastin time \>upper limit of normal (ULN)~ * International normalized ratio \>ULN~ * Alanine aminotransferase \>ULN~ * Aspartate aminotransferase \>ULN~ * Total bilirubin \>ULN~ * Serum creatinine ≥1.5 mg/dL~ * Hemoglobin \<lower limit of normal (LLN)~ * Hematocrit \<LLN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Apixaban, 10 mg (whole tablets) (Type: EXPERIMENTAL): Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
- Apixaban, 10 mg (crushed and suspended in water) (Type: EXPERIMENTAL): Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
- Apixaban, 10 mg (crushed and mixed with applesauce) (Type: EXPERIMENTAL): Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce

Based on this trial design, predict the completion outcome and termination type (if applicable).